<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20210520095447+02'00'</creation_date><modification_date>D:20210520095617+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-13-846_h_epar-other_1.pdf</pdf_file></head><body><section><header>official address  domenico scarlattilaan 6  ●  1083 hs amsterdam  ●  the netherlands an agency of the european union     address for visits and deliveries  refer to www.ema.europa.eu/how-to-find-us  send us a question  go to www.ema.europa.eu/contact  telephone +31 (0)88 781 6000   © european medicines agency, 2021. reproduction is authorised provided the source is acknowledged. 
 22 april 2021 ema/285965/2021  
 committee for medicinal products for human use (chmp) 
 scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) 
  active substance(s): enzalutamide  procedure no. emea/h/c/psusa/00010095/202008 
  period covered by the psur: 30 august 2017 to 30 august 2020 
      scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)  
 ema/285965/2021
  
 page 2/2</header></section><section><header>scientific conclusions</header><p>taking into account the prac assessment report on the psur(s) for enzalutamide, the scientific conclusions of chmp are as follows:</p><p>
 in view of available data on dysgeusia from clinical trial, post-marketing cases and in view of the class 
 effect, the prac considers a causal relationship between enzalutamide and dysgeusia is at least a 
 reasonable possibility. the prac concluded that the product information of products containing 
 enzalutamide should be amended accordingly. 
 the chmp agrees with the scientific conclusions made by the prac.</p></section><section><header>grounds for the variation to the terms of the marketing authorisation(s)</header><p>on the basis of the scientific conclusions for enzalutamide the chmp is of the opinion that the benefit-risk balance of the medicinal product(s) containing enzalutamide is unchanged subject to the proposed 
 changes to the product information 
 the chmp recommends that the terms of the marketing authorisation(s) should be varied.</p></section></body></xml>